Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golidocitinib + corticosteroid
- Development stage
- Unknown
- Lead developer
- Dizal Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Golidocitinib + corticosteroid is an investigational combination therapy being studied for the treatment of rapidly progressive interstitial lung disease (RP-ILD), particularly in patients with anti-MDA5 antibody-positive dermatomyositis. The regimen consists of golidocitinib (DZD4205), a potent and highly selective Janus kinase 1 (JAK1) inhibitor developed by Dizal Pharma, administered alongside standard-of-care corticosteroids (such as methylprednisolone or prednisone). Golidocitinib works by inhibiting the JAK-STAT signaling pathway, thereby suppressing the production of pro-inflammatory cytokines like interferon-gamma, which are central to the pathogenesis of RP-ILD. Corticosteroids provide complementary broad-spectrum anti-inflammatory and immunosuppressive effects. This combination is currently being evaluated in Phase 2 clinical trials to determine its efficacy in improving lung function and reducing mortality in this life-threatening condition.
- Other names
- golidocitinib plus corticosteroid
02
Targets
GR (Glucocorticoid receptor)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on golidocitinib + corticosteroid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golidocitinib + corticosteroid.